RABBIT at a Glance
|Long-term monitoring of safety and efficacy of therapy with biologics, biosimilars and JAK inhibitors in patients with rheumatoid arthritis (RA) compared to therapy with conventional, synthetic DMARDs|
|Prospective observational study|
|Rheumatologists in practice or special outpatient departments throughout Germany. The participation of new facilities is possible at any time! Please register via the contact form|
|Patients with confirmed RA diagnosis by the rheumatologist stating the ACR criteria of 1987,|
disability age >=16 years,
start of a new therapy with a biologic, biosimilar or JAK inhibitor or
restart of a therapy with a biologic, biosimilar or JAK inhibitor after at least a three-month therapy break or
start of a therapy with a conventional DMARD after failure of at least a conventional DMARD therapy.
Patients who start therapy with Remicade® have not been able to start treatment with a conventional DMARD since January 1, 2017 and patients who start a new Inflectra® therapy since January 1, 2018.03.2018 are no longer included in RABBIT.
|Questionnaires for physician and patient at the time of inclusion (at the beginning of the new therapy), after 3 and 6 months and at 6-month intervals thereafter|
|At least 5 years|
time required for the physiciant
For the base bow approx. 15-30 minutes per patient,
for a follow-up sheet about 10 to 15 minutes per patient
|Study management||Pharmacoepidemiology working group of the German Rheumatism Research Center in Berlin|